Here, PD1/PD-L1 blockade is currently the main ICB treatment for various types of cancer, such as melanoma, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal adenocarcinoma (GEA) [1]. This evidence concerns the gene CD274 and renal cell carcinoma.